Working to Eradicate Gynecologic Cancers

Douglas A. Levine, MD

Associate Member
Memorial Sloan Kettering Cancer Center
Gynecology Service/Dept. of Surgery
1275 York Avenue
New York, NY
USA 10065


Biographical Sketch:
Dr. Douglas Levine is an Associate Attending Surgeon at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Levine earned his medical doctorate in 1995 at Mount Sinai Medical Center, where he also completed a residency in obstetrics and gynecology. He went on to a clinical fellowship in gynecologic oncology at Memorial Sloan-Kettering and then spent 2 years as a postdoctoral research fellow, also at Memorial. In addition to a clinical practice, Dr. Levine is the current Head of the Gynecology Research Laboratory, where he studies the genomic science of ovarian and endometrial carcinoma. Dr. Levine is very active within the NIH-sponsored Cancer Genome Atlas project (TCGA). He serves as co-chair of the Ovarian and Endometrial Disease Working Groups and has been responsible for providing a translational focus to the genomic analyses of the projects. In addition to these responsibilities, Dr. Levine is a member of the editorial board of Gynecologic Oncology and a member of the Scientific Advisory Committee of the Ovarian Cancer Research Fund. He has authored or co-authored more than 90 peer-reviewed articles and two textbooks. Dr. Levine receives funding from the National Cancer Institute, the Department of Defense, Stand Up 2 Cancer, and the Gynecologic Oncology Group."

Papers:
26 Tumor-derived serum exosomal microRNA as a novel biomarker for high-grade serous carcinoma 77 Outcomes of patients with stage I endometrial cancer in the sentinel lymph node era 88 Impact of obesity on sentinel lymph node mapping in patients with newly diagnosed uterine cancer undergoing robotic surgery 91 A multicenter prospective assessment of surgical findings associated with suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube and peritoneal cancer 104 Improvement in rates of cytoreduction to no residual for stages IIIB-IV ovarian, fallopian tube and primary peritoneal cancer: a change in surgical approach and individualized surgeon feedback 109 Cost-effectiveness analysis of conventional laparoscopic versus robotically assisted laparoscopic adnexal surgery for benign indications performed by gynecologic oncologists 144 Relationship between Body Mass Index (BMI) and gene expression profiles of high grade serous ovarian cancers in The Cancer Genome Atlas (TCGA) project 244 Sentinel lymph node mapping in patients with vulvar malignancies using indocyanine green and near-infrared imaging: preliminary detection rate experience 292 Combined preoperative and extended pharmacologic venous thromboembolic prophylaxis in patient undergoing surgery for advanced adnexal malignancies 335 Integrated genomic analysis of STIC-associated high-grade serous carcinoma 446 Predictive value of the age-adjusted Charlson comorbidity index on perioperative complications and survival in patients undergoing surgery for advanced ovarian cancer Moderator Distillation of Genetics of Uterine Cancer Introductory Remarks